← Back to Home

From Tumor Sequencing to Vaccine Manufacturing: India’s PopVax Launches Personalized mRNA Cancer Vaccine Services

The Hyderabad-based RNA Foundry connects AI antigen screening with small-batch manufacturing, estimating that most projects will take 8 to 10 weeks and cost approximately US$300,000. Manufacturing capabilities are gradually taking shape, while evidence of safety and efficacy in humans remains to be established.

By SURL BioNews

Designing a vaccine for each cancer patient involves more than finding a tumor’s vulnerabilities. It also requires turning distinct genetic sequences into products of reliable quality for research use. Hyderabad-based Indian startup PopVax is working to connect these steps: in collaboration with Stochastic Sciences, it provides contract research, development, and manufacturing services for personalized mRNA cancer vaccines through RNA Foundry.

According to The New Indian Express, these cancer vaccine candidates remain in development and have not yet been administered to patients. The company plans to work initially with a small number of physicians and patients outside India, seeking to provide products through named-patient or compassionate-use pathways by the end of 2026, subject to the relevant regulatory permissions. Such access pathways do not mean that a product has received general marketing approval.

The design process begins with sequencing data from a patient’s tumor. The team searches for mutations that may produce “neoantigens,” then selects sequences suitable for encoding in mRNA. Cells are expected to read these instructions and produce tumor markers for the immune system to recognize, helping T cells target cancer cells. This is a therapeutic strategy being developed for existing cancers, and the company says it is intended for use alongside current treatments.

AI helps screen candidate sequences in this process. RNA Foundry says its workflow combines AI models, major histocompatibility complex (MHC) antigen presentation predictions, and immunogenicity prediction tools; clients can also submit sequences they have designed themselves. These calculations aim to assess which fragments are more likely to be recognized by the immune system, but the public pages do not provide the models’ training data, independent validation performance, or human efficacy data for this personalized cancer vaccine service. Several hurdles remain between predicted recognition and actual tumor control.

On the manufacturing side, mRNA is encapsulated in lipid nanoparticles (LNPs) to aid delivery. PopVax says its Hyderabad facility integrates research and development with clinical-dose manufacturing that has GMP production capabilities, covering lipid synthesis through to finished mRNA-LNP products, with analysis and quality control conducted primarily on site. Tests listed by RNA Foundry include RNA identity and integrity, particle size, encapsulation efficiency, sterility, and endotoxin testing. These tests help establish product quality, but cannot replace assessments of human safety and anticancer effects.

RNA Foundry estimates that most projects cost approximately US$300,000 and take 8 to 10 weeks, with actual timelines dependent on manufacturing slot availability. The company also says it has the capacity to manufacture more than 100 personalized cancer vaccines over the next 12 months. These are all company estimates of costs, turnaround times, and capacity, rather than numbers of patients who have completed treatment or success rates. The published timeline also cannot be directly interpreted as a patient’s waiting time from seeking medical care to vaccination.

This service makes the path from sequence design to physical manufacturing more concrete for personalized vaccines, while also highlighting the next question: how to continue building evidence of quality, safety, and efficacy when each patient’s product is different. For PopVax, whether the factory can deliver is only one hurdle. Whether the vaccine candidates can trigger effective antitumor immune responses, improve clinical outcomes, and meet regulatory requirements where they are used still needs to be verified step by step.

References

  1. The New Indian Express on MSN
  2. RNA Foundry / PopVax
  3. PopVax